Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14365548 | 0.80 | — | — | |
| SCHEMBL15871999 | 0.78 | HRH4 (0.32) | HRH4HRH3 | |
| SCHEMBL14200517 | 0.78 | — | — | |
| SCHEMBL19002630 | 0.74 | POLB (0.40) | — | |
| SCHEMBL14365546 | 0.74 | — | — | |
| SCHEMBL4671779 | 0.73 | — | — | |
| SCHEMBL12258940 | 0.73 | HRH4 (0.33) | HRH4HRH3 | |
| SCHEMBL14228546 | 0.73 | HRH4 (0.33) | HRH4HRH3 | |
| SCHEMBL1302384 | 0.71 | NPSR1 (0.51) | — | |
| SCHEMBL18792499 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198705-B2 | Hybrid Amphotericin B derivatives with reduced toxicity | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-12-14 | — | — | US | disclosed |
| US-10882883-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | ELION THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882883-B2 | Derivatives of amphotericin B | C9, ERG28, AMPD3 | HRH4 800/4885HRH3 653/4885 |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | C9, ERG28, AMPD3 | HRH4 800/4885HRH3 653/4885 |
| US-11198705-B2 | Hybrid Amphotericin B derivatives with reduced toxicity | ERG28, BAK1, MCL1 | HRH4 2163/4885HRH3 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.